Dr. Kilgour is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Broadway St
Fl 4
Redwood City, CA 94063Phone+1 650-723-6316
Education & Training
Stanford Health Care-Sponsored Stanford UniversityResidency, Dermatology, 2022 - 2025
California Pacific Medical CenterInternship, Internal Medicine, 2021 - 2022
Stanford Health CarePost-Doctoral Fellowship, 2019 - 2021
University of OxfordAcademic Foundation Programme, Dermatology, 2017 - 2019
The University of Wales College of MedicineClass of 2017, MBBCh(Hons), Honours- Cardiff UniversityBSc(Hons), Medical Education, Honours, 2014 - 2015
Certifications & Licensure
CA State Medical License 2021 - 2026
AR State Medical License 2024 - 2025
Publications & Presentations
PubMed
- 4 citationsTreatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat.James M. Kilgour, Aatman Shah, Shaundra Eichstadt, Irene Bailey, Sumaira Z. Aasi
JAMA Dermatology. 2021-11-17 - 6 citationsPhase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma.James M. Kilgour, Aatman Shah, Nicole M. Urman, Shaundra Eichstadt, H. Do
Clinical Cancer Research. 2021-09-01 - 13 citationsReview of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics.James M. Kilgour, Justin L. Jia, Kavita Y. Sarin
Cancers. 2021-07-31
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
